当前位置： SCI文献检索 > CANCER CHEMOTHERAPY AND PHARMACOLOGY期刊下所有文献 > Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule.

Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule.

Abstract：

PURPOSE:Our aim was to develop an optimal sampling strategy for the description of the pharmacokinetics of rubitecan and its active metabolite 9-aminocamptothecin (9-AC) for use in phase II/III studies with oral rubitecan administered in a daily times five schedule. METHODS:Concentration-time data of rubitecan and 9-AC were obtained from 14 patients who had received 1.5 mg/m(2) per day rubitecan orally. Population pharmacokinetic analysis of both the parent and the metabolite was performed using the nonlinear mixed effect modelling program (NONMEM). Optimal sampling points were selected on the basis of the assessed population pharmacokinetic parameters using a D-optimality algorithm. RESULTS:The pharmacokinetics of both rubitecan and 9-AC were adequately described with a one-compartment model. The absorption rate constant, apparent volume of distribution and apparent clearance of rubitecan were 0.81 h(-1), 50 l and 1.7 l/h, respectively. For 9-AC the corresponding values of the apparent volume of distribution and the elimination rate constant were 51 l and 0.102 h(-1). Interindividual variability of the pharmacokinetic parameters ranged from 38% to 49%. For the first dose, optimal sampling points were 1, 3, 5, 8 and 24 h after dosing. Monte Carlo simulations indicated that the sampling schedule produced parameter estimates which were unbiased and precise. CONCLUSIONS:An optimal sampling schedule was derived which allowed assessment of the pharmacokinetic parameters of both the parent compound and its metabolite 9-AC after oral administration of rubitecan.

journal_name

Cancer Chemother Pharmacol

journal_title

Cancer chemotherapy and pharmacology

authors

Schoemaker NE,Mathôt RA,Schöffski P,Rosing H,Schellens JH,Beijnen JH

doi

10.1007/s00280-002-0516-5

keywords:

subject

Has Abstract

pub_date

2002-12-01 00:00:00

pages

514-7

issue

6

eissn

0344-5704

issn

1432-0843

journal_volume

50

pub_type

临床试验,杂志文章,随机对照试验

相关文献

CANCER CHEMOTHERAPY AND PHARMACOLOGY文献大全
  • Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts.

    abstract：PURPOSE:The purpose of this study was to assess the therapeutic and toxicological effects of cesium chloride (CsCl) administration in mice bearing prostate cancer tumors. METHODS:Three CsCl dose titration studies were completed in tumor-bearing and non-tumor-bearing athymic nude mice. All mice were administered either...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0429-4

    authors： Low JC,Wasan KM,Fazli L,Eberding A,Adomat H,Guns ES

    更新日期：2007-11-01 00:00:00

  • Chemotherapy in the management of invasive bladder cancer. A review.

    abstract：:In this review of the management of invasive carcinoma of the bladder the results of primary and systemic therapies are evaluated in the light of the natural history of the disease. The clinical and pathological causes of treatment failure are assessed in an attempt to identify new approaches that may be used in the f...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,评审

    doi：10.1007/BF00254978

    authors： Bush H,Thatcher N,Barnard R

    更新日期：1979-01-01 00:00:00

  • Pharmacokinetics and metabolism of O-(chloroacetyl-carbamoyl) fumagillol (TNP-470, AGM-1470) in rhesus monkeys.

    abstract：:The metabolic disposition and pharmacokinetics of TNP-470 were investigated in rhesus monkeys following intravenous administration of 5 mg/kg of [3H]-TNP-470. Rapid and extensive metabolism of parent drug to six metabolites occurred as demonstrated by the absence of unchanged drug in plasma and urine at time points as...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050458

    authors： Cretton-Scott E,Placidi L,McClure H,Anderson DC,Sommadossi JP

    更新日期：1996-01-01 00:00:00

  • Low dose--high dose: what is the right dose? Pharmacokinetic modeling of etoposide.

    abstract：PURPOSE:Some clinical studies on etoposide (Eto) have shown marked schedule dependency of the effect (starting at about 1 mg/l) and toxicity (over about 10 mg/l) whereas other studies have not confirmed these results. What are the conclusions we can draw from these inconsistent results when developing new low-dose (LD)...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-001-0418-y

    authors： Würthwein G,Boos J

    更新日期：2002-04-01 00:00:00

  • Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing.

    abstract：PURPOSE:Abiraterone acetate (AA) was recently approved for castration-resistant prostate cancer in Japan. Two phase 1 studies were conducted to assess the pharmacokinetics of abiraterone after single-dose administration in Japanese healthy men and to evaluate the effects of food timing on abiraterone pharmacokinetics a...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1007/s00280-014-2616-4

    authors： Inoue K,Shishido A,Vaccaro N,Jiao J,Stieltjes H,Bernard A,Yu M,Chien C

    更新日期：2015-01-01 00:00:00

  • Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study.

    abstract：PURPOSE:To determine the efficacy and safety of the combination therapy with docetaxel and cisplatin (CDDP) at low doses in elderly patients with advanced NSCLC. PATIENTS AND METHODS:A total of 42 patients aged > or =70 years with previously untreated advanced NSCLC received docetaxel 75 mg/m(2) plus CDDP 50 mg/m(2) o...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s00280-008-0749-z

    authors： Feliu J,Firvida JL,Castro J,Madroñal C,Rodríguez-Jaráiz A,Salgado M,Belda-Iniesta C,Casado E,García-Mata J,González-Barón M,Oncopaz Cooperative Group.

    更新日期：2009-02-01 00:00:00

  • A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).

    abstract：PURPOSE:Gemcitabine/cisplatin combination therapy has been the standard palliative chemotherapy for patients with advanced biliary tract cancer (BTC). We aimed to evaluate the efficacy and safety of adding S-1 to gemcitabine/cisplatin combination therapy for patients with advanced BTC. METHODS:Patients with histologic...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s00280-014-2648-9

    authors： Kanai M,Hatano E,Kobayashi S,Fujiwara Y,Marubashi S,Miyamoto A,Shiomi H,Kubo S,Ikuta S,Yanagimoto H,Terajima H,Ikoma H,Sakai D,Kodama Y,Seo S,Morita S,Ajiki T,Nagano H,Ioka T

    更新日期：2015-02-01 00:00:00

  • Changes in serum iron levels following very high-dose cisplatin.

    abstract：:A four-fold (P less than 0.001) mean increase in iron levels was found in 18 patients (a total of 36 courses of therapy) with ovarian cancer at the end of a 5-day course of cisplatin (40 mg/m2 per day every 4-5 weeks). The kinetics of these modifications began very early (24-48 h after initiation of therapy): they rea...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00252983

    authors： Pollera CF,Ameglio F,Reina S,Nardi M,Abbolito MR,Parracino C

    更新日期：1987-01-01 00:00:00

  • Improved survival among patients enrolled in oncology phase 1 trials in recent decades.

    abstract：PURPOSE:This study aimed to compare the survival of patients enrolled in phase 1 trials in recent decades. METHODS:The medical records of consecutive patients with advanced cancer who participated in single-agent oncology phase 1 trials from 1995 to 2015 at a single institution were retrospectively investigated. RESU...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-019-03992-2

    authors： Ebata T,Shimizu T,Koyama T,Shimomura A,Iwasa S,Kondo S,Kitano S,Yonemori K,Fujiwara Y,Yamamoto N

    更新日期：2020-02-01 00:00:00

  • Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications.

    abstract：:Lung cancer is the leading cause of cancer death in the world. Recently, targeted therapy and anti-programmed cell death receptor 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) immunotherapy have made great progress in treatment of lung cancer. However, responses to these therapies are variable, influenced b...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,评审

    doi：10.1007/s00280-018-3586-8

    authors： Huang C,Liu S,Tong X,Fan H

    更新日期：2018-08-01 00:00:00

  • Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib.

    abstract：PURPOSE:The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) is approved for cancer treatment. We investigated whether gefitinib treatment can enhance human EGF (hEGF) uptake in vitro, thereby increasing the potential of hEGF as a vehicle for EGFR-targeted therapy. METHODS:W...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-013-2198-6

    authors： He P,Li G

    更新日期：2013-08-01 00:00:00

  • Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects.

    abstract：OBJECTIVE:To characterize the population pharmacokinetics of plitidepsin (Aplidin) in cancer patients. METHODS:A total of 283 patients (552 cycles) receiving intravenous plitidepsin as monotherapy at doses ranging from 0.13 to 8.0 mg/m(2) and given as 1- or 24-h infusions every week; 3- or 24-h infusion biweekly; or 1...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,meta分析

    doi：10.1007/s00280-008-0841-4

    authors： Nalda-Molina R,Valenzuela B,Ramon-Lopez A,Miguel-Lillo B,Soto-Matos A,Perez-Ruixo JJ

    更新日期：2009-06-01 00:00:00

  • Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab.

    abstract：PURPOSE:The purpose of this study was to evaluate the expression of ser-miRNAs at different periods during treatment and analyze their relationship with therapeutic response and prognosis in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab (NCCT). METHODS:Venous blood w...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-019-03937-9

    authors： Liu B,Su F,Lv X,Zhang W,Shang X,Zhang Y,Zhang J

    更新日期：2019-11-01 00:00:00

  • Methylene blue is more toxic to erythroleukemic cells than to normal peripheral blood mononuclear cells: a possible use in chemotherapy.

    abstract：:Methylene blue (MB) is a phenothiazine with radio and photosensitizing properties and anti-tumoral activity. Our group has shown that MB was capable of inhibiting the in vitro growth of erythroleukemic cells with multidrug resistance (MDR). However, there are no studies comparing the cytotoxicity of this molecule for ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-005-1014-3

    authors： Kirszberg C,Rumjanek VM,Capella MA

    更新日期：2005-12-01 00:00:00

  • Pharmacokinetics and metabolism of hexamethylmelamine in mice after IP administration.

    abstract：:The pharmacokinetics of hexamethylmelamine (HMM) and its first metabolite (hydroxymethylpentamethylmelamine: HMPMM) following IP bolus dose of 200 mg/kg were studied in mice. The drug concentrations were determined by a sensitive reversed-phase HPLC assay. Thus, for the first time, HMM major hydroxylated and demethyla...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00273391

    authors： Dubois J,Atassi G,Hanocq M,Abikhalil F

    更新日期：1986-01-01 00:00:00

  • Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo.

    abstract：:The activity of CD437¿6-[3-(1-adamantyl)-4 hydroxyphenyl]-2-naphthalene carboxylic acid¿, a relatively selective activator of RAR-gamma, was evaluated against four human ovarian-carcinoma cell lines : PE01, PE04 (a Pt-resistant in vivo-derived counterpart of PE01), PE01CDDP (a Pt-resistant in vitro-derived model of PE...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050841

    authors： Langdon SP,Rabiasz GJ,Ritchie AA,Reichert U,Buchan P,Miller WR,Smyth JF

    更新日期：1998-01-01 00:00:00

  • Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs.

    abstract：PURPOSE:The observation that the orphan drug dichloroacetate (DCA) selectively promotes mitochondria-regulated apoptosis and inhibits tumour growth in preclinical models by shifting the glucose metabolism in cancer cells from anaerobic to aerobic glycolysis attracted not only scientists', clinicians' but also patients'...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-010-1361-6

    authors： Heshe D,Hoogestraat S,Brauckmann C,Karst U,Boos J,Lanvers-Kaminsky C

    更新日期：2011-03-01 00:00:00

  • RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide.

    abstract：PURPOSE:Aldehyde dehydrogenases class-1A1 (ALDH1A1) and class-3A1 (ALDH3A1) have been associated with resistance to cyclophosphamide (CP) and its derivatives. We have previously reported the downregulation of these enzymes by all-trans retinoic acid (ATRA). METHODS:In this study, we used siRNA duplexes as well as retr...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-006-0233-6

    authors： Moreb JS,Mohuczy D,Ostmark B,Zucali JR

    更新日期：2007-01-01 00:00:00

  • Relationship between tumor cell density and drug concentration and the cytotoxic effects of doxorubicin or vincristine: mechanism of inoculum effects.

    abstract：:When tumor cell density increases, the cytotoxic activity of certain anticancer agents, such as vincristine (VCR) and doxorubicin (DXR), progressively decreases. This phenomenon is termed the inoculum effect. Since VCR and DXR are less active in an acidic environment, we questioned whether the inoculum effects could h...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00695987

    authors： Kobayashi H,Takemura Y,Ohnuma T

    更新日期：1992-01-01 00:00:00

  • Potential role of acid ceramidase in conversion of cytostatic to cytotoxic end-point in pancreatic cancer cells.

    abstract：PURPOSE:Acid ceramidase (AC) occupies an important place in the control of cancer cell proliferation. We tested the influence of AC inhibition on the effects of PSC 833, a P-glycoprotein antagonist with potent ceramide-generating capacity, to determine whether AC could be a therapeutic target in pancreatic cancer. MET...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-012-2050-4

    authors： Morad SA,Messner MC,Levin JC,Abdelmageed N,Park H,Merrill AH Jr,Cabot MC

    更新日期：2013-03-01 00:00:00

  • Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.

    abstract：:Unidirectional blood-brain barrier transfer of the lipophilic anticancer agents vincristine and vinblastine was studied in anesthetized rats, using an isolated, in situ brain perfusion technique. Drug binding to plasma constituents was also measured. Despite the high lipophilicity of these agents (the log octanol/phys...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF02897227

    authors： Greig NH,Soncrant TT,Shetty HU,Momma S,Smith QR,Rapoport SI

    更新日期：1990-01-01 00:00:00

  • Etoposide sensitivity of radioresistant human glioma cell lines.

    abstract：PURPOSE:Malignant gliomas display aggressive local behavior and are not cured by existing therapy. Etoposide, a topoisomerase-II-inhibitor agent, is one of the most active and useful antineoplastic agents. However, etoposide is not usually used on these tumors. We undertook an in vitro study to prove that etoposide is ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050713

    authors： Beauchesne P,Bertrand S,N'guyen MJ,Christianson T,Dore JF,Mornex F,Bonner JA

    更新日期：1998-01-01 00:00:00

  • Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo.

    abstract：OBJECTIVE:To study the pharmacokinetics of neamine in rats and to evaluate its anti-cervical cancer activity. METHODS:The plasma level of neamine was determined by HPLC-ELSD. Pharmacokinetic parameters were calculated using DAS 2.0 software. Tissue microarray analysis was conducted to examine angiogenin (ANG) expressi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-014-2658-7

    authors： Liu Y,Zhang X,An S,Wu Y,Hu G,Wu Y

    更新日期：2015-03-01 00:00:00

  • Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.

    abstract：PURPOSE:To investigate the synergistic cytotoxicity of TRAIL in combination with chemotherapeutic agents in A549 cell lines, we systematically evaluated the cytotoxicity of TRAIL alone and TRAIL in combination with cisplatin, paclitaxel (Taxol) or actinomycin D in A549 cell lines in vitro and in vivo, and whether the s...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-004-0867-1

    authors： Fan QL,Zou WY,Song LH,Wei W

    更新日期：2005-02-01 00:00:00

  • Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.

    abstract：PURPOSE:The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects. METHODS:Six subjects received a single oral dose of 800 mg ¹⁴C-sonidegib (74 kBq, 2.0 µCi) under fasting conditions. Blood, plasma, urine, and fecal samples wer...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-014-2468-y

    authors： Zollinger M,Lozac'h F,Hurh E,Emotte C,Bauly H,Swart P

    更新日期：2014-07-01 00:00:00

  • Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure.

    abstract：INTRODUCTION:High cut-off dialysis, increasingly used in multiple myeloma patients, is susceptible to influence anticancer drug elimination. We report about lenalidomide disposition in a patient on high cut-off dialysis for renal failure secondary to myeloma cast nephropathy. METHODS:The patient received a higher dosa...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-016-3219-z

    authors： Dao K,Lu Y,Peer CJ,Figg WD,Stadelmann R,Burnier M,Buclin T,Kissling S

    更新日期：2017-01-01 00:00:00

  • Lack of in vivo cross-resistance with 4'-thio-ara-C against drug-resistant murine P388 and L1210 leukemias.

    abstract：PURPOSE:4'-Thio-β-D-arabinofuranosylcytosine (4'-thio-ara-C), which has shown a broad spectrum of antitumor activity against human tumor systems in mice and is undergoing clinical trials, was evaluated for cross-resistance to seven clinical agents in order to identify potentially useful guides for patient selection for...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-010-1498-3

    authors： Waud WR,Gilbert KS,Secrist JA 3rd

    更新日期：2011-08-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.

    abstract：:Topotecan is a novel semisynthetic derivative of the anticancer agent camptothecin and inhibits the intranuclear enzyme topoisomerase I. The lactone structure of topotecan, which is in equilibrium with the inactive ring-opened hydroxy acid, is essential for this activity. We performed a pharmacokinetics study as part ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s002800050479

    authors： van Warmerdam LJ,Creemers GJ,Rodenhuis S,Rosing H,de Boer-Dennert M,Schellens JH,ten Bokkel Huinink WW,Davies BE,Maes RA,Verweij J,Beijnen JH

    更新日期：1996-01-01 00:00:00

  • Neoadjuvant chemotherapy for epithelial ovarian cancer--role of apoptosis.

    abstract：BACKGROUND:Ovarian cancer is one of the most frequently fatal gynecological cancers because most cases are diagnosed at an advanced stage. Loss of growth control and a marked resistance to apoptosis are considered major mechanisms driving tumor progression. Little is known about the effect of various treatment regimens...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s00280-004-0993-9

    authors： Dutta T,Sharma H,Kumar L,Dinda AK,Kumar S,Bhatla N,Singh N

    更新日期：2005-10-01 00:00:00

  • Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer.

    abstract：PURPOSE:Preclinical research and prior clinical observations demonstrated reduced toxicity and suggested enhanced efficacy of cisplatin due to folic acid and vitamin B12 suppletion. In this randomized phase 2 trial, we evaluated the addition of folic acid and vitamin B12 to first-line palliative cisplatin and gemcitabi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s00280-018-3588-6

    authors： van Zweeden AA,van Groeningen CJ,Honeywell RJ,Giovannetti E,Ruijter R,Smorenburg CH,Giaccone G,Verheul HMW,Peters GJ,van der Vliet HJ

    更新日期：2018-07-01 00:00:00